Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

63.12 -0.96 (-1.51%)
Streaming Delayed Price Updated: 3:28 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition ↗
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now. 
Via InvestorPlace
News headline image
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024 ↗
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation. ↗
Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN). 
Via Chartmill
News headline image
Looking Into Biomarin Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
Recap: Biomarin Pharmaceutical Q4 Earnings ↗
 
Via Benzinga
News headline image
Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
While growth is established for NASDAQ:BMRN, the stock's valuation remains reasonable. ↗
Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability. 
Via Chartmill
News headline image
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered. 
Via The Motley Fool
Topics Stocks
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. 
Via Chartmill
News headline image
7 Biotech Stocks Fighting America’s Deadliest Diseases ↗
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
News headline image
3 No-Brainer Stocks to Buy With $200 Right Now ↗
A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses. 
Via The Motley Fool
News headline image
Earnings Outlook For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
15 Analysts Have This to Say About Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗
A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains. 
Via The Motley Fool
Topics Stocks
News headline image
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month. 
Via InvestorPlace
News headline image
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗
An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping. 
Via The Motley Fool
Topics Stocks
News headline image
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
News headline image
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
News headline image
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗
A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains. 
Via The Motley Fool
Topics Stocks
News headline image
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today? ↗
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a  
Via Benzinga
News headline image
3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗
These three lesser-known biotech companies are profitable and growing revenue. 
Via The Motley Fool
News headline image
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in  
Via Benzinga
News headline image
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗
A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors. 
Via The Motley Fool
Topics Stocks
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023 ↗
 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.